{"schema_version":"secwatch.filing_event.v1","accession":"0001390478-26-000004","form_type":"8-K","ticker":"SLS","cik":"0001390478","company_name":"SELLAS Life Sciences Group, Inc.","filed_at":"2026-03-19T23:59:59+00:00","discovered_at":"2026-05-14T18:02:34.970381+00:00","generated_at":"2026-05-15T09:36:26.018215+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"SELLAS reports FY2025 net loss $26.9M ($0.25/shr); cash $71.8M; Phase 3 REGAL AML trial approaching final analysis","bullets":["FY2025 net loss $26.9M ($0.25/shr) vs $30.9M ($0.50/shr) in FY2024; cash $71.8M at Dec 31, 2025.","Received additional $42.6M from warrant exercises in Q1 2026, strengthening balance sheet.","Phase 3 REGAL trial of GPS in AML nearing final analysis at 80 events; 72 events as of Dec 26, 2025.","Phase 2 SLS009 in r/r AML showed 46% ORR; expansion into newly diagnosed AML underway, first patient dosed.","European collaboration with IMPACT-AML to study SLS009 in ~40 newly diagnosed AML patients; enrollment expected Q2 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001390478-26-000004","json":"https://secwatch.observer/filing/0001390478-26-000004.json","markdown":"https://secwatch.observer/filing/0001390478-26-000004.md","text":"https://secwatch.observer/filing/0001390478-26-000004.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1390478/000139047826000004/0001390478-26-000004-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1390478/000139047826000004/sls-20260319.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T09:36:26.018215+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"def940bde5502b9eed93a2ecd8612d30143a3d96","claim":"SELLAS Life Sciences Group, Inc. reported financial results for the full year ended December 31, 2025.","evidence_excerpt":"SELLAS Life Sciences Group, Inc. (“SELLAS”) issued a press release (the “Press Release”) announcing its financial results for the year ended December 31, 2025 and providing a corporate update.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1390478/000139047826000004/0001390478-26-000004-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the full year ended December 31, 2025"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}